Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy


About this study

The purpose of this trial is to confirm if benralizumab can reduce OCS dependence (after dose optimisation) in patients who are uncontrolled on high-dose ICS-LABA, and chronically dependent on OCS as part of their regular asthma controller regimen.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  1. Provision of informed consent prior to any study specific procedures
  2. Female and male aged from 18 to 75 years, inclusively
  3. History of physician-diagnosed asthma requiring treatment with medium dose ICS and a LABA
  4. Elevated level of peripheral blood eosinophil
  5. Documented treatment with high-dose ICS and LABA for at least 6 months prior to Visit 1
  6. Chronic oral prednisone or prednisolone therapy for at least 6 continuous months directly preceding Visit 1, and on a stable dose for at least one month prior to Visit 1
  7. Patients with documented failures of OCS reduction within 6 months prior to Visit 1 will not be required to proceed through the dose optimization phase during run-in.
  8. Morning pre-bronchodilator (Pre-BD) FEV1 of <80% predicted
  9. Either documented post bronchodilator (post-BD) reversibility of ≥ 12% and ≥ 200 mL in FEV1 or PC20 FEV1
  10. At least 1 documented asthma exacerbation in the previous 12 months prior to the date informed consent is obtained
  11. Optimized OCS dose reached at least 2 weeks prior to randomization
  12. Additional asthma controller medication must not have been initiated during run-in period
  13. At least 70% compliance with OCS use
  14. At least 70% compliance with usual asthma controller ICS-LABA
  15. Minimum 70% (i.e. 10 of 14 days) compliance with asthma daily diary (morning and evening diary)
  16. No documented asthma exacerbations during the screening/dose optimization period

Exclusion criteria:

  1. Clinically important pulmonary disease other than asthma or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts.
  2. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:
    • Affect the safety of the patient throughout the study
    • Influence the findings of the studies or their interpretations
    • Impede the patient's ability to complete the entire duration of study
  3. Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date informed consent is obtained or during the screening/run-in period
  4. Any clinically significant abnormal findings in physical examination, vital signs, haematology, clinical chemistry, or urinalysis during screening/run-in period, which in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study
  5. History of life-threatening asthma
  6. Asthma control reached at an OCS dose of ≤5mg during run-in/OCS optimization phase
  7. Qualifies for 3 consecutive dose reductions at Visits 2-4 and continues to meet OCS dose reduction criteria at Visit 5
  8. Receipt of oral dexamethasone as the maintenance oral steroid controller for asthma symptoms

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

John Hagan, M.D.

Closed for enrollment

More information


  • Many patients with severe asthma rely on oral glucocorticoids to manage their disease. We investigated whether benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor that significantly reduces the incidence of asthma exacerbations, was also effective as an oral glucocorticoid-sparing therapy in patients relying on oral glucocorticoids to manage severe asthma associated with eosinophilia. Read More on PubMed

Mayo Clinic Footer